Aristeia Capital’s Psyence Biomedical Warrant PBMWW Stock Holding History

Aristeia Capital’s Portfolio PBMWW Stock Details PBMWW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.62K	Sell	115,319 -100,000	-46%	-$2.87K	﹤0.01%	786
2026 Q1	$3.91K	Sell	215,319 -32,538	-13%	-$625	﹤0.01%	692
2025 Q4	$3.92K	Hold	247,857	–	–	﹤0.01%	599
2025 Q3	$6.43K	Hold	247,857	–	–	﹤0.01%	525
2025 Q2	$5.02K	Hold	247,857	–	–	﹤0.01%	475
2025 Q1	$4.2K	Sell	247,857 -25,000	-9%	-$475	﹤0.01%	422
2024 Q4	$3.79K	Hold	272,857	–	–	﹤0.01%	373
2024 Q3	$3.1K	Hold	272,857	–	–	﹤0.01%	361
2024 Q2	$4.04K	Hold	272,857	–	–	﹤0.01%	327
2024 Q1	$19.5K	Buy	+272,857	New	+$17K	﹤0.01%	237

Other funds holding PBMWW

HCI

Harraden Circle Investments New York $784M AUM 20.59% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Aristeia Capital's PBMWW Position: Q2 2026 in Review

Aristeia Capital reduced its Psyence Biomedical Warrant (PBMWW) stake by 46% in Q2 2026, selling an estimated $2.87K and leaving 115,319 shares worth $2.62K. The position accounts for ﹤0.01% of the portfolio, ranked #786.

Aristeia Capital first reported a position in PBMWW in Q1 2024 and has held it in 10 quarters since. The position peaked at $19.5K in Q1 2024. 18 funds tracked by Wall St. Rank hold PBMWW as of Q2 2026.

Aristeia Capital held 115,319 shares of Psyence Biomedical Warrant worth $2.62K as of Q2 2026.
Aristeia Capital sold 100,000 Psyence Biomedical Warrant shares in Q2 2026, an estimated $2.87K.
Psyence Biomedical Warrant made up ﹤0.01% of Aristeia Capital's portfolio in Q2 2026, its #786 holding.
Aristeia Capital first reported a position in Psyence Biomedical Warrant in Q1 2024 and has held it in 10 quarters since.
Aristeia Capital's Psyence Biomedical Warrant position peaked at $19.5K in Q1 2024.
18 funds tracked by Wall St. Rank held Psyence Biomedical Warrant as of Q2 2026.

Based on Aristeia Capital's 13F filing for Q2 2026, filed 14 Aug 2026.